ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Neurolithium®:Pharmafactory AG Oligosol Vertretungen
Complete information for professionalsDDDPrint 
Galenic Form / Therapeutic GroupComposition.EffectsPharm.kinetikIndication.UsageRestrictions.Unwanted effects
Interactions.OverdoseOther adviceSwissmedic-Nr.Last update of information 
N05AN01 - LithiumATC-DDD Version 2016. Source: WHO
N - Nervous System
 
N05 - Psycholeptics

The group is divided into therapeutic subgroups:
N05A - Antipsychotics
N05B - Anxiolytics
N05C - Hypnotics and sedatives

N05A - Antipsychotics

This group comprises drugs with antipsychotic actions (i.e. neuroleptics).
Reserpine is classified in C02 - Antihypertensives.
Antipsychotics in combination with antidepressants are classified in N06C - Psycholeptics and psychoanaleptics in combination.
The group is subdivided mainly according to chemical structure.

The DDDs are based on the treatment of psychosis. The substances in this group are sometimes used for other indications in much lower doses.
For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.

N05AN - Lithium
 

The DDD is based on the prophylaxis of mania or depression.

N05AN01 - Lithium
DoseRoute of administrationNote
 O 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home